Percutaneous valve replacement

A paradigm shift

Anjan Sinha, Annapoorna S. Kini, Samin K. Sharma

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Valvular heart disease is often associated with significant morbidity and mortality. Surgical treatment of stenotic or regurgitant valvular lesions can alter the natural history of the disease process, yielding excellent short and long-term results, meaning that this has been accepted as the gold standard for therapy of valvular disease. Surgical procedures can be associated with a significant rate of perioperative complications, however. These procedures are particularly associated with unacceptably high short and long-term morbidity and mortality in the elderly - a population group that has grown steadily over the years. Elderly patients often have significant comorbidities that preclude a safe and durable surgical correction of the valvular lesions in up to 31% of these high-risk cases. This review provides an overview of recent developments in percutaneous valve therapeutics. RECENT FINDINGS: Over the last decade, numerous technical developments in valvular interventions have focused on percutaneous valve replacement. There are percutaneous valve replacements on the horizon that promise to offer a novel approach to correct valvular lesions, especially in this high-risk surgical population. SUMMARY: Several devices are presently being evaluated in feasibility trials, and many new ones are being developed. Results with semilunar valves have generally been better than the atrioventricular valves. Long-term results of these treatment modalities are still unknown.

Original languageEnglish
Pages (from-to)471-477
Number of pages7
JournalCurrent Opinion in Cardiology
Volume22
Issue number5
DOIs
StatePublished - Sep 2007

Fingerprint

Morbidity
Heart Valve Diseases
Mortality
Therapeutics
Population Groups
Comorbidity
Equipment and Supplies
Population

Keywords

  • Percutaneous intervention
  • Valvular heart disease
  • Valvuloplasty

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Percutaneous valve replacement : A paradigm shift. / Sinha, Anjan; Kini, Annapoorna S.; Sharma, Samin K.

In: Current Opinion in Cardiology, Vol. 22, No. 5, 09.2007, p. 471-477.

Research output: Contribution to journalArticle

Sinha, Anjan ; Kini, Annapoorna S. ; Sharma, Samin K. / Percutaneous valve replacement : A paradigm shift. In: Current Opinion in Cardiology. 2007 ; Vol. 22, No. 5. pp. 471-477.
@article{b1f2493575e74558adbc90f541caf0fe,
title = "Percutaneous valve replacement: A paradigm shift",
abstract = "PURPOSE OF REVIEW: Valvular heart disease is often associated with significant morbidity and mortality. Surgical treatment of stenotic or regurgitant valvular lesions can alter the natural history of the disease process, yielding excellent short and long-term results, meaning that this has been accepted as the gold standard for therapy of valvular disease. Surgical procedures can be associated with a significant rate of perioperative complications, however. These procedures are particularly associated with unacceptably high short and long-term morbidity and mortality in the elderly - a population group that has grown steadily over the years. Elderly patients often have significant comorbidities that preclude a safe and durable surgical correction of the valvular lesions in up to 31{\%} of these high-risk cases. This review provides an overview of recent developments in percutaneous valve therapeutics. RECENT FINDINGS: Over the last decade, numerous technical developments in valvular interventions have focused on percutaneous valve replacement. There are percutaneous valve replacements on the horizon that promise to offer a novel approach to correct valvular lesions, especially in this high-risk surgical population. SUMMARY: Several devices are presently being evaluated in feasibility trials, and many new ones are being developed. Results with semilunar valves have generally been better than the atrioventricular valves. Long-term results of these treatment modalities are still unknown.",
keywords = "Percutaneous intervention, Valvular heart disease, Valvuloplasty",
author = "Anjan Sinha and Kini, {Annapoorna S.} and Sharma, {Samin K.}",
year = "2007",
month = "9",
doi = "10.1097/HCO.0b013e3282a14dc8",
language = "English",
volume = "22",
pages = "471--477",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Percutaneous valve replacement

T2 - A paradigm shift

AU - Sinha, Anjan

AU - Kini, Annapoorna S.

AU - Sharma, Samin K.

PY - 2007/9

Y1 - 2007/9

N2 - PURPOSE OF REVIEW: Valvular heart disease is often associated with significant morbidity and mortality. Surgical treatment of stenotic or regurgitant valvular lesions can alter the natural history of the disease process, yielding excellent short and long-term results, meaning that this has been accepted as the gold standard for therapy of valvular disease. Surgical procedures can be associated with a significant rate of perioperative complications, however. These procedures are particularly associated with unacceptably high short and long-term morbidity and mortality in the elderly - a population group that has grown steadily over the years. Elderly patients often have significant comorbidities that preclude a safe and durable surgical correction of the valvular lesions in up to 31% of these high-risk cases. This review provides an overview of recent developments in percutaneous valve therapeutics. RECENT FINDINGS: Over the last decade, numerous technical developments in valvular interventions have focused on percutaneous valve replacement. There are percutaneous valve replacements on the horizon that promise to offer a novel approach to correct valvular lesions, especially in this high-risk surgical population. SUMMARY: Several devices are presently being evaluated in feasibility trials, and many new ones are being developed. Results with semilunar valves have generally been better than the atrioventricular valves. Long-term results of these treatment modalities are still unknown.

AB - PURPOSE OF REVIEW: Valvular heart disease is often associated with significant morbidity and mortality. Surgical treatment of stenotic or regurgitant valvular lesions can alter the natural history of the disease process, yielding excellent short and long-term results, meaning that this has been accepted as the gold standard for therapy of valvular disease. Surgical procedures can be associated with a significant rate of perioperative complications, however. These procedures are particularly associated with unacceptably high short and long-term morbidity and mortality in the elderly - a population group that has grown steadily over the years. Elderly patients often have significant comorbidities that preclude a safe and durable surgical correction of the valvular lesions in up to 31% of these high-risk cases. This review provides an overview of recent developments in percutaneous valve therapeutics. RECENT FINDINGS: Over the last decade, numerous technical developments in valvular interventions have focused on percutaneous valve replacement. There are percutaneous valve replacements on the horizon that promise to offer a novel approach to correct valvular lesions, especially in this high-risk surgical population. SUMMARY: Several devices are presently being evaluated in feasibility trials, and many new ones are being developed. Results with semilunar valves have generally been better than the atrioventricular valves. Long-term results of these treatment modalities are still unknown.

KW - Percutaneous intervention

KW - Valvular heart disease

KW - Valvuloplasty

UR - http://www.scopus.com/inward/record.url?scp=34548451099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548451099&partnerID=8YFLogxK

U2 - 10.1097/HCO.0b013e3282a14dc8

DO - 10.1097/HCO.0b013e3282a14dc8

M3 - Article

VL - 22

SP - 471

EP - 477

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 5

ER -